BROADCASTS.com

b'Carl Quintanilla, Jim Cramer and David Faber explored the road ahead for stocks on a day in which the S&P 500 and Nasdaq each hit fresh record intraday highs. Cramer says "this is one of the more buoyant markets I\'ve ever seen". He explains why this is the case and outlines his upside case for names such as FedEx, Darden Restaurants and Nike. The anchors also reacted to Goldman Sachs\' note on inflation and supply chain disruptions. Boeing under pressure after the FAA informed the jet maker it is not likely to receive certification for its 777X long-range aircraft until mid-to-late 2023 at the earliest. The anchors also took a closer look at the "CRISPR rally": Shares of Intellia Therapeutics and other gene-editing firms soaring after the company and its partner Regeneron announced positive results in a phase 1 study of a gene-editing treatment for a genetic nerve disorder. Also on the biotech front: Capitol Hill lawmakers announced an investigation into the approval and pricing of Biogen\'s Alzheimer\'s drug. Also in focus: How Virgin Galactic shares are trading after soaring 39% on Friday, AMC Theatres announced its busiest weekend at the box office since the pandemic, Universal Pictures\' "F9" topped the weekend box office with $70 million in North American ticket sales -- the biggest debut for any movie since the pandemic began (Universal is owned by CNBC parent Comcast), UBS to allow hybrid working arrangements for many of its employees, Nvidia reportedly receiving support for its planned $40 billion takeover of ARM from some of the UK chip maker\\u2019s major customers. Cramer explains why he sees Nvidia shares jumping to the $900 mark.'